GetTopicDetailResponse(id=4a82680e6f, topicName=ensifentrine, introduction=ensifentrine, content=null, image=null, comments=2, allHits=1157, url=https://h5.medsci.cn/topic?id=6807, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=99772, tagList=[TagDto(tagId=99772, tagName=ensifentrine)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2212112, encodeId=23432212112d2, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a> <a href='/topic/show?id=f5885086f1' target=_blank style='color:#2F92EE;'>#COPD#</a> <a href='/topic/show?id=4a82680e6f' target=_blank style='color:#2F92EE;'>#ensifentrine#</a>, objectTitle=FDA批準PDE3/4抑制劑ensifentrine用于成人COPD的維持治療，這是首個吸入式療法, objectType=article, longId=832229, objectId=ad88832229e5, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719557460080_4754896.png, objectUrl=/article/show_article.do?id=ad88832229e5, replyNumber=0, likeNumber=183, createdTime=2024-06-28, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=ad88832229e5, moduleTitle=FDA批準PDE3/4抑制劑ensifentrine用于成人COPD的維持治療，這是首個吸入式療法, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=ad88832229e5)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1785686, encodeId=982c1e85686d7, content=<a href='/topic/show?id=4a82680e6f' target=_blank style='color:#2F92EE;'>#ensifentrine#</a>, objectTitle=霧化Ensifentrine治療慢性阻塞性肺疾?。–OPD）：即將開展III期臨床試驗, objectType=article, longId=201330, objectId=7e8920133089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e8920133089, replyNumber=0, likeNumber=116, createdTime=2021-04-20, rootId=0, userName=12498cf9m35(暫無昵稱), userId=d47b2500175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e8920133089, moduleTitle=霧化Ensifentrine治療慢性阻塞性肺疾?。–OPD）：即將開展III期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7e8920133089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785685, encodeId=2b001e85685ae, content=<a href='/topic/show?id=4a82680e6f' target=_blank style='color:#2F92EE;'>#ensifentrine#</a>, objectTitle=Verona Pharma公布ensifentrine作為慢性阻塞性肺?。–OPD）維持治療的II期臨床結(jié)果, objectType=article, longId=188170, objectId=28501881e0e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28501881e0e2, replyNumber=0, likeNumber=90, createdTime=2020-11-29, rootId=0, userName=12498cf9m35(暫無昵稱), userId=d47b2500175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28501881e0e2, moduleTitle=Verona Pharma公布ensifentrine作為慢性阻塞性肺病（COPD）維持治療的II期臨床結(jié)果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=28501881e0e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
